Congratulations to @PoolbegPharma CEO, @jerskillington, PhD, on being named Biopharma & Life Sciences Connected Person of the Month for May 2026 by Ingenious Media. 👏👏👏👏
A well-deserved recognition of Jeremy’s leadership at #POLB and his significant contribution to Ireland’s thriving life sciences sector.
🔹 20+ years of industry experience
🔹 Proven biotech leadership
🔹 Driving innovation in cancer immunotherapy and infectious disease
Congratulations, Jeremy, on this fantastic achievement and recognition of your hard work and dedication Sir!
#Biotech #LifeSciences #Leadership #PoolbegPharma
🚨 #ROAD delivers again! 👀
💰 A further £14 million has now been received following the second tranche of the CSS Put Option.
🔑 Key points:
✅ £14m cash received
✅ Funds to support the acquisition of Hoch Group
✅ Final tranche still to come…
✅ Potential for a further £20m from the remaining CSS stake in September 2027
This is another significant milestone as @ROAD_RealEstate continues to strengthen its balance sheet and execute its growth strategy.
The cash is real. The optionality remains. Plenty for investors to keep an eye on.
https://t.co/5eVNVcP0Py
🩺Another important milestone for @PoolbegPharma
✅ First clinical site activated for the #POLB 001 TOPICAL trial
✅ Patient recruitment now underway
✅ Interim data remains on track for Summer 2026
Key points :
🔹 POLB 001 is being evaluated as a potential preventative treatment for Cytokine Release Syndrome (CRS), a serious side effect associated with cancer immunotherapies.
🔹 Trial involves relapsed/refractory multiple myeloma patients receiving approved bispecific antibody teclistamab.
🔹 With CRS typically occurring within days to weeks of treatment, the study offers the potential for a rapid data readout.
Strong investigator engagement and an area of significant unmet medical need continue to support the opportunity for POLB 001.
A key operational milestone achieved, with the next catalyst now firmly in sight. 👀💥
#POLB #Biotech #Oncology #CancerImmunotherapy
https://t.co/iIyGj9z17V
📰 "Everything is going right for this in-demand property stock"
Following the latest trading update, @IChronicle has reaffirmed its positive outlook for RentGuarantor.
Read all about it ⤵️
https://t.co/fUSsVbbgBy
Welcome to socialist Britain, where rewards are no longer a reflection of effort
We now live in a country where a family living on benefits in London can be better off than a household earning £70,000 per year, https://t.co/V6n1ubkLGK
KEY POINT 👀
Why did #HVO release this as a formal RNS rather than an RNS Reach ⁉️🧐
Because this feels bigger than simply promoting a Capital Markets Day.
@hVIVO_UK appears to be signalling:
➡️ “Pay attention to where this business is GOING… not where it WAS.”
This isn’t just Human Challenge Trials anymore.
The strategy now spans:
✅ Early clinical development
✅ Human challenge trials
✅ Patient trials
✅ Specialist laboratory services
✅ End-to-end support for biotech & pharma
Names involved matter too:
🔹 Boehringer Ingelheim
🔹 RA Capital
��� ILiAD Biotechnologies
🔹 Decoy Therapeutics
When companies start actively reshaping how institutions and analysts view the future business model… smart investors tend to pay attention 👀
Less noise.
More signal.
https://t.co/Nq1YXGRm4W
#AIM #SmallCaps #Biotech #ClinicalTrials